- Home
- CLSD
as 07-26-2024 4:00pm EST
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | ALPHARETTA |
| Market Cap: | 93.4M | IPO Year: | 2016 |
| Target Price: | $4.60 | AVG Volume (30 days): | 129.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.65 - $2.12 | Next Earning Date: | 08-12-2024 |
| Revenue: | $8,452,000 | Revenue Growth: | 758.94% |
| Revenue Growth (this year): | -92.78% | Revenue Growth (next year): | 618.34% |
Stock Insider Trading Activity of Clearside Biomedical Inc. (CLSD)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chong Ngai Hang Victor | CLSD | Chief Medical Officer | Jun 24 '24 | Buy | $1.06 | 23,500 | $24,910.00 | 63,500 | SEC Form 4 |
| YERXA BENJAMIN R | CLSD | Director | May 15 '24 | Buy | $1.31 | 7,813 | $10,235.03 | 17,957 | SEC Form 4 |
| Gibney Anthony S | CLSD | Director | Apr 17 '24 | Buy | $1.30 | 93,290 | $121,277.00 | 100,000 | SEC Form 4 |
| Gibney Anthony S | CLSD | Director | Apr 17 '24 | Buy | $1.25 | 6,710 | $8,387.50 | 6,710 | SEC Form 4 |
| Chong Ngai Hang Victor | CLSD | CHIEF MEDICAL OFFICER | Mar 20 '24 | Buy | $1.60 | 30,000 | $48,000.00 | 30,000 | SEC Form 4 |
| WHITMORE BRADFORD T | CLSD | 10% Owner | Feb 7 '24 | Buy | $1.35 | 444,444 | $599,999.40 | 4,495,034 | SEC Form 4 |
| Deignan Charles A. | CLSD | Chief Financial Officer | Jan 18 '24 | Sell | $1.28 | 12,900 | $16,512.00 | 384,662 | SEC Form 4 |
| LASEZKAY GEORGE M | CLSD | CEO | Jan 18 '24 | Sell | $1.27 | 18,000 | $22,860.00 | 466,577 | SEC Form 4 |
Latest Clearside Biomedical Inc. News
CLSD Breaking Stock News: Dive into CLSD Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET
GlobeNewswire
16 days ago
Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board
GlobeNewswire
a month ago
Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery
MT Newswires
a month ago
Oppenheimer Initiates Clearside Biomedical at Outperform With $5 Price Target
GlobeNewswire
a month ago
Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting
Reuters
2 months ago
Spirit Airlines not considering Chapter 11 bankruptcy, CNBC reports
GlobeNewswire
2 months ago
Aqua-Tots Swim School Splashes Into Summer With Highly-Anticipated Grand Opening in Henderson, Nevada
GlobeNewswire
2 months ago
BW Energy: Mandatory notifications of trade by primary insiders and close associates
Compare CLSD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLSD Clearside Biomedical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.